Aurinia Pharmaceuticals (AUPH) reported a robust third quarter in 2025, with LUPKYNIS sales climbing 27% year-over-year, spurred by its inclusion in key treatment guidelines. Total revenue reached $73.5 million, marking an 8% increase from the previous year. The company raised its 2025 revenue outlook to $275-$280 million. Net income surged 119% to $31.6 million, while diluted earnings per share grew 130% to $0.23. Cash flow from operations also saw a significant boost, rising 162% to $44.5 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.